Aurinia is a late clinical stage biopharmaceutical company focused on developing and commercializing therapies in disease areas of high unmet medical need. We are currently developing voclosporin, an investigational drug, for the treatment of lupus nephritis (LN) and focal segmental glomerularsclerosis (FSGS). Additionally, we are advancing voclosporin ophthalmic solution (VOS), a topical formulation, for the treatment of dry eye syndrome (DES).
Company Information
Company Profile
Contact Information
Investor Relations
Glenn Schulman, PharmD, MPH
Senior Vice President, Corporate Communications and Investor Relations
IR@auriniapharma.com
Company Contact
Aurinia Pharmaceuticals Inc.
#1203-4464 Markham Street
Victoria, BC V8Z 7X8